BR9808441A - Pharmaceutical composition for administration to an animal, carrier vector, vectors for carrying and expressing selected genes in escherichia coli and a strain of mycobacterium, process for administering to an animal an effective amount of the pharmaceutical composition, and culture medium. - Google Patents

Pharmaceutical composition for administration to an animal, carrier vector, vectors for carrying and expressing selected genes in escherichia coli and a strain of mycobacterium, process for administering to an animal an effective amount of the pharmaceutical composition, and culture medium.

Info

Publication number
BR9808441A
BR9808441A BR9808441-0A BR9808441A BR9808441A BR 9808441 A BR9808441 A BR 9808441A BR 9808441 A BR9808441 A BR 9808441A BR 9808441 A BR9808441 A BR 9808441A
Authority
BR
Brazil
Prior art keywords
animal
pharmaceutical composition
mycobacterium
vectors
administering
Prior art date
Application number
BR9808441-0A
Other languages
Portuguese (pt)
Inventor
Abdel Hakim Labidi
Original Assignee
Cytoclonal Pharmaceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoclonal Pharmaceutics Inc filed Critical Cytoclonal Pharmaceutics Inc
Publication of BR9808441A publication Critical patent/BR9808441A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Abstract

'COMPOSIçãO FARMACêUTICA PARA ADMINISTRAçãO A UM ANIMAL, VETOR TRANSPORTADOR, VETORES PARA TRANSPORTAR E EXPRESSAR GENES SELECIONADOS EM ESCHERICHIA COLI E DE UMA CEPA DE MYCOBACTERIUM, PROCESSO PARA ADMINISTRAR A UM ANIMAL UMA QUANTIDADE EFICAZ DA COMPOSIçãO FARMACêUTICA, E, MEIO DE CULTURA". As vacinas recombinantes de mycobacterium para tratamento de doenças intracelulares, que foram desenvolvidas utilizando-se um sistema de liberação de antígeno na forma de cepas de Mycobacterium, um sistema de transferência genética na forma de vetores não patogênicos de clonagem e de expressão, e tecnologias relacionadas, para prover produtos combinando adjuvantes não tóxicos de Mycobacterium de imuno-regulação, antígenos não tóxicos oxógenos imunoestimulantes específicos para uma variedade de doenças, e quantidades não tóxicas de citocinas, que reforçam a trajetória de T~ H~-1. Os vetores de Mycobacterium de clonagem e de expressão incluem tanto os vetores extranucleares quanto os integrativos.'PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION TO AN ANIMAL, VECTOR TRANSPORT, VECTORS FOR TRANSPORTING AND EXPRESSING GENES SELECTED IN COLI ESCHERICHIA AND A MYCOBACTERIUM STRUCTURE, PROCESS FOR ADMINISTERING AN ANIMAL AN EFFECTIVE QUANTITY AND COMPOSITION. recombinant mycobacterium vaccines for the treatment of intracellular diseases, which were developed using an antigen delivery system in the form of Mycobacterium strains, a gene transfer system in the form of non-pathogenic cloning and expression vectors, and related technologies, to provide products combining non-toxic immunocompromising Mycobacterium adjuvants, non-toxic immunostimulating antigen-specific antigens for a variety of diseases, and non-toxic amounts of cytokines, which reinforce the trajectory of T ~ H ~ -1. cloning and expression include both the extra vectors both nuclear and integrative.

BR9808441-0A 1997-03-28 1998-03-27 Pharmaceutical composition for administration to an animal, carrier vector, vectors for carrying and expressing selected genes in escherichia coli and a strain of mycobacterium, process for administering to an animal an effective amount of the pharmaceutical composition, and culture medium. BR9808441A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4284997P 1997-03-28 1997-03-28
PCT/US1998/006056 WO1998044096A2 (en) 1997-03-28 1998-03-27 Mycobacterium recombinant vaccines

Publications (1)

Publication Number Publication Date
BR9808441A true BR9808441A (en) 2000-05-23

Family

ID=21924071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808441-0A BR9808441A (en) 1997-03-28 1998-03-27 Pharmaceutical composition for administration to an animal, carrier vector, vectors for carrying and expressing selected genes in escherichia coli and a strain of mycobacterium, process for administering to an animal an effective amount of the pharmaceutical composition, and culture medium.

Country Status (6)

Country Link
EP (1) EP0973881A2 (en)
JP (1) JP2001518781A (en)
AU (1) AU6780498A (en)
BR (1) BR9808441A (en)
CA (1) CA2284736A1 (en)
WO (1) WO1998044096A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1951001A (en) * 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
EP1369127B1 (en) * 2001-02-20 2010-04-14 MARUHO Co., Ltd. Novel medicinal use of alpha antigen or alpha antigen gene
WO2003006035A1 (en) * 2001-07-10 2003-01-23 Stanford Rook Limited Anti-emetic compositions comprising mycobacterial material
WO2013039069A1 (en) 2011-09-13 2013-03-21 日本ビーシージー製造株式会社 Novel recombinant bcg vaccine
CN108285881B (en) * 2018-01-04 2021-06-08 广州大学 Mycobacterium with synchronous electricity generation and denitrification activity and application thereof
BR112020016704A2 (en) * 2018-02-19 2020-12-15 Universidad De Zaragoza COMPOSITIONS FOR USE AS A PROPHYLACTIC AGENT FOR THOSE AT RISK OF TUBERCULOSIS INFECTION, OR AS SECONDARY AGENTS FOR TREATING PATIENTS INFECTED WITH TUBERCULOSIS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
CA2045842A1 (en) * 1990-07-16 1992-01-17 William R. Jacobs Dna capable of site-specific integration into mycobacteria
AU660430B2 (en) * 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
EP0625052A4 (en) * 1991-10-21 1995-07-19 Medimmune Inc Bacterial expression vectors containing dna encoding secretion signals of lipoproteins.

Also Published As

Publication number Publication date
CA2284736A1 (en) 1998-10-08
AU6780498A (en) 1998-10-22
WO1998044096A2 (en) 1998-10-08
JP2001518781A (en) 2001-10-16
WO1998044096A3 (en) 1999-01-14
EP0973881A2 (en) 2000-01-26

Similar Documents

Publication Publication Date Title
Jalava et al. Bacterial ghosts as vaccine candidates for veterinary applications
Kong et al. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment
Jones et al. Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration
Curtiss et al. Selective delivery of antigens by recombinant bacteria
Lorenzen et al. Genetic vaccination of rainbow trout against viral haemorrhagic septicaemia virus: small amounts of plasmid DNA protect against a heterologous serotype
ES2192555T3 (en) BASIC VECTORS OF ADD ASSOCIATED VIRUS 2.
Waine et al. Nucleic acids: vaccines of the future
CN1902317B (en) Plasmid maintenance
Shiau et al. Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis
BR9808441A (en) Pharmaceutical composition for administration to an animal, carrier vector, vectors for carrying and expressing selected genes in escherichia coli and a strain of mycobacterium, process for administering to an animal an effective amount of the pharmaceutical composition, and culture medium.
EP0804230B1 (en) Vaccine against mycobacterial infections
Ding et al. Attenuated Listeria monocytogenes protecting zebrafish (Danio rerio) against Vibrio species challenge
Fry et al. Gene gun DNA immunization of cattle induces humoral and CD4 T-cell-mediated immune responses against the Theileria parva polymorphic immunodominant molecule
CN102335421A (en) Attenuated salmonella inducible secretory expression oral vaccine presentation system and application thereof
U'ren et al. Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity
Atkins et al. Recombinant Salmonella vaccines for biodefence
JPS60120822A (en) Immunogenic blend
Zhu et al. The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimurium
Yin et al. Construction and immunogenicity of a DNA vaccine containing clumping factor A of Staphylococcus aureus and bovine IL18
Hughes Cytokine adjuvants: lessons from the past—guidelines for the future?
Lee et al. Stable expression of a foreign gene, delivered by gene gun, in the muscle of rainbow trout Oncorhynchus mykiss
Groschup et al. Modified Feist broth as a serum-free alternative for enhanced production of protective antigen of Erysipelothrix rhusiopathiae
Keane-Myers et al. Evolution of electroporated DNA vaccines
Russell et al. Antibody responses of goldfish (Carassius auratus L.) to DNA-immunisation at different temperatures and feeding levels
Ramalingaswami Importance of vaccines in child survival

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.